Fras Juan, P
left alone, it can progress to MASH, fibrosis, and cirrhosis. Tirzepatide trials in MASLD/MASH show meaningful drops in liver fat, liver enzymes, and inflammatory changes on biopsy, with higher rates of NASH/MASH resolution and fibrosis improvement compared with placebo. Semaglutide also improves MASLD and MASH: phase 2 and phase 3 work, plus large realworld cohorts, link it to better liver histology, less fibrosis progression, and improved survival in MASLD patients versus controls. Both drugs are legitimate liverprotection tools in metabolic disease
Carnitine has a highly conserved biosynthetic pathway
Start with an in-person evaluation, including in house lab tests and body measurements
Fresta CG, Fidilio A, Lazzarino G, Musso N, Grasso M, Merlo S, et al